Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiovascular disease in individuals with CKD. Elevated levels of FGF23 have been linked to greater risks of LVH and mortality in patients with CKD, but whether these risks represent causal effects of FGF23 is unknown. Here, we report that elevated FGF23 levels are independently associated with LVH in a large, racially diverse CKD cohort. FGF23 caused pathological hypertrophy of isolated rat cardiomyocytes via FGF receptor–dependent activation of the calcineurin-NFAT signaling pathway, but this effect was independent of klotho, the coreceptor for FGF23 in the kidney and parathyroid glands. Intramyocardial or intravenous injection of FGF23 in wild-type mice resulted in LVH, and klotho-deficient mice demonstrated elevated FGF23 levels and LVH. In an established animal model of CKD, treatment with an FGF–receptor blocker attenuated LVH, although no change in blood pressure was observed. These results unveil a klotho-independent, causal role for FGF23 in the pathogenesis of LVH and suggest that chronically elevated FGF23 levels contribute directly to high rates of LVH and mortality in individuals with CKD.
Christian Faul, Ansel P. Amaral, Behzad Oskouei, Ming-Chang Hu, Alexis Sloan, Tamara Isakova, Orlando M. Gutiérrez, Robier Aguillon-Prada, Joy Lincoln, Joshua M. Hare, Peter Mundel, Azorides Morales, Julia Scialla, Michael Fischer, Elsayed Z. Soliman, Jing Chen, Alan S. Go, Sylvia E. Rosas, Lisa Nessel, Raymond R. Townsend, Harold I. Feldman, Martin St. John Sutton, Akinlolu Ojo, Crystal Gadegbeku, Giovana Seno Di Marco, Stefan Reuter, Dominik Kentrup, Klaus Tiemann, Marcus Brand, Joseph A. Hill, Orson W. Moe, Makoto Kuro-o, John W. Kusek, Martin G. Keane, Myles Wolf
Title and authors | Publication | Year |
---|---|---|
FGF23 signaling impairs neutrophil recruitment and host defense during CKD
Jan Rossaint, Jessica Oehmichen, Hugo Van Aken, Stefan Reuter, Hermann Pavenstädt, Melanie Meersch, Mark Unruh, Alexander Zarbock |
Journal of Clinical Investigation | 2016 |
Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease
S Singh, A Grabner, C Yanucil, K Schramm, B Czaya, S Krick, MJ Czaja, R Bartz, R Abraham, GS di Marco, M Brand, M Wolf, C Faul |
Kidney International | 2016 |
Stop chronic kidney disease progression: Time is approaching
UA el Din, MM Salem, DO Abdulazim |
World Journal of Nephrology | 2016 |
Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness
DE Leaf, KA Jacob, A Srivastava, ME Chen, M Christov, H Jüppner, VS Sabbisetti, A Martin, M Wolf, SS Waikar |
Journal of the American Society of Nephrology : JASN | 2016 |
Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study
N Souma, T Isakova, D Lipiszko, RL Sacco, MS Elkind, JT DeRosa, SJ Silverberg, AJ Mendez, C Dong, CB Wright, M Wolf |
The Journal of clinical endocrinology and metabolism | 2016 |
Inflammation regulates fibroblast growth factor 23 production:
C Francis, V David |
Current Opinion in Nephrology and Hypertension | 2016 |
FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde
G Cianciolo, M Cozzolino |
Clinical Kidney Journal | 2016 |
Cardiac actions of fibroblast growth factor 23
C Faul |
Bone | 2016 |
Fibroblast Growth Factor-23—A Potential Uremic Toxin
P Kuczera, M Adamczak, A Wiecek |
Toxins | 2016 |
Fibroblast growth factor 23: fueling the fire
M Hanudel, H Jüppner, IB Salusky |
Kidney International | 2016 |
Clinical features of CKD-MBD in Japan: cohort studies and registry
T Hamano, Y Sakaguchi, N Fujii, Y Isaka |
Clinical and Experimental Nephrology | 2016 |
Extrarenal effects of FGF23
D Haffner, M Leifheit-Nestler |
Pediatric Nephrology | 2016 |
Ironing out the cross talk between FGF23 and inflammation
V David, C Francis, JL Babitt |
American journal of physiology. Renal physiology | 2016 |
Roles of FGF Signals in Heart Development, Health, and Disease
N Itoh, H Ohta, Y Nakayama, M Konishi |
Frontiers in Cell and Developmental Biology | 2016 |
CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
ML Melamed, RS Buttar, M Coco |
Advances in Chronic Kidney Disease | 2016 |
Fibroblast growth factor-23 and renin–angiotensin system levels in vitamin-D-dependent rickets type I
C Cuervo, CL Abitbol, GE Zilleruelo, M Freundlich |
Pediatric Nephrology | 2016 |
Vitamins & Hormones
JA Neyra, MC Hu |
Vitamins & Hormones | 2016 |
FGF23 from bench to bedside
CP Kovesdy, LD Quarles |
American journal of physiology. Renal physiology | 2016 |
Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho
S Yamada, CM Giachelli |
Bone | 2016 |
Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study
W Chen, ML Melamed, TH Hostetter, C Bauer, AC Raff, AL Almudevar, A Lalonde, S Messing, MK Abramowitz |
BMC Nephrology | 2016 |
Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure
M Imazu, H Takahama, M Amaki, Y Sugano, T Ohara, T Hasegawa, H Kanzaki, T Anzai, N Mochizuki, H Asanuma, M Asakura, M Kitakaze |
Hypertension Research | 2016 |
The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy:
A Grabner, C Faul |
Current Opinion in Nephrology and Hypertension | 2016 |
Genetic insights into the mechanisms of Fgf signaling
JR Brewer, P Mazot, P Soriano |
Genes & development | 2016 |
DNMT1 and HDAC2 Cooperate to Facilitate Aberrant Promoter Methylation in Inorganic Phosphate-Induced Endothelial-Mesenchymal Transition
X Tan, X Xu, M Zeisberg, EM Zeisberg, O El-Maarri |
PloS one | 2016 |
Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells
B Richter, J Haller, D Haffner, M Leifheit-Nestler |
Pflügers Archiv - European Journal of Physiology | 2016 |
Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β-blocker treatment
A Fajol, H Chen, AT Umbach, LD Quarles, F Lang, M Föller |
The FASEB Journal | 2016 |
Phosphate Toxicity in CKD: The Killer among Us
CS Ritter, E Slatopolsky |
Clinical journal of the American Society of Nephrology : CJASN | 2016 |
Nutrition in Cardioskeletal Health
KM Gallant, CM Weaver, DA Towler, SV Thuppal, RL Bailey |
Advances in nutrition (Bethesda, Md.) | 2016 |
Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease
X Lu, MC Hu |
Kidney Diseases | 2016 |
Bidirectional Translation in Cardiovascular Calcification
CS Hilaire, M Liberman, JD Miller |
Arteriosclerosis, thrombosis, and vascular biology | 2016 |
Fibroblast Growth Factor-23 and Frailty in Elderly Community-Dwelling Individuals: The Cardiovascular Health Study
T Beben, JH Ix, MG Shlipak, MJ Sarnak, LF Fried, AN Hoofnagle, M Chonchol, BR Kestenbaum, IH de Boer, DE Rifkin |
Journal of the American Geriatrics Society | 2016 |
Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial
J Tuñón, I González-Hernández, L Llanos-Jiménez, J Alonso-Martín, JM Escudier-Villa, N Tarín, C Cristóbal, P Sanz, AM Pello, Á Aceña, R Carda, M Orejas, M Tomás, P Beltrán, MC Rueda, E Marcos, JM Serrano-Antolín, C Gutiérrez-Landaluce, R Jiménez, J Cabezudo, A Curcio, G Peces-Barba, E González-Parra, R Muñoz-Siscart, ML González-Casaus, A Lorenzo, A Huelmos, J Goicolea, B Ibáñez, G Hernández, LM Alonso-Pulpón, J Farré, Ó Lorenzo, I Mahíllo-Fernández, J Egido |
BMJ Open | 2016 |
Skeletal Muscle, but not Cardiovascular Function, Is Altered in a Mouse Model of Autosomal Recessive Hypophosphatemic Rickets
MJ Wacker, CD Touchberry, N Silswal, L Brotto, CJ Elmore, LF Bonewald, J Andresen, M Brotto |
Frontiers in physiology | 2016 |
Calcium as a cardiovascular toxin in CKD-MBD
SM Moe |
Bone | 2016 |
The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder:
ME Seifert, KA Hruska |
Transplantation | 2016 |
Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery
DE Leaf, M Christov, H Jüppner, E Siew, TA Ikizler, A Bian, G Chen, VS Sabbisetti, JV Bonventre, X Cai, M Wolf, SS Waikar |
Kidney International | 2016 |
Counter-regulatory paracrine actions of FGF-23 and 1,25(OH) 2 D in macrophages
X Han, L Li, J Yang, G King, Z Xiao, LD Quarles, W Ellmeier |
FEBS Letters | 2016 |
Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease
R Martín-Reyes, JA Franco-Peláez, Ó Lorenzo, ML González-Casaus, AM Pello, Á Aceña, R Carda, JL Martín-Ventura, L Blanco-Colio, ML Martín-Mariscal, J Martínez-Milla, R Villa-Bellosta, A Piñero, F Navarro, J Egido, J Tuñón, J Devaney |
PloS one | 2016 |
Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway
KK Stevens, L Denby, RK Patel, PB Mark, S Kettlewell, GL Smith, MJ Clancy, C Delles, AG Jardine |
Nephrology Dialysis Transplantation | 2016 |
Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson Heart Study
N Bansal, R Katz, J Himmelfarb, M Afkarian, B Kestenbaum, IH de Boer, B Young |
Nephrology Dialysis Transplantation | 2016 |
Fibroblast growth factor-23 and chronic allograft injury in pediatric renal transplant recipients: a Midwest Pediatric Nephrology Consortium study
ME Seifert, IF Ashoor, ML Chiang, AS Chishti, DJ Dietzen, DS Gipson, HS Janjua, DT Selewski, KA Hruska |
Pediatric Transplantation | 2016 |
Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?
RF Dubin, SJ Shah |
Current Heart Failure Reports | 2016 |
A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation:
M Wolf, MR Weir, N Kopyt, RB Mannon, JV Visger, H Deng, S Yue, F Vincenti |
Transplantation | 2016 |
Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease
C Zhou, F Wang, JW Wang, LX Zhang, MH Zhao |
Chinese Medical Journal | 2016 |
Fibroblast Growth Factor 23 and Risk of CKD Progression in Children
AA Portale, MS Wolf, S Messinger, F Perwad, H Ju ppner, BA Warady, SL Furth, IB Salusky |
Clinical journal of the American Society of Nephrology : CJASN | 2016 |
Silent Cerebral Microbleeds and Longitudinal Risk of Renal and Cardiovascular Events in Patients with CKD
H Shima, T Mori, M Ooi, M Sonoda, T Shoji, E Ishimura, M Okamura, N Ishizaka, M Inaba |
Clinical journal of the American Society of Nephrology : CJASN | 2016 |
FGF23 in chronic kidney disease: are we lost in translation?
J Bacchetta |
BoneKEy Reports | 2016 |
Connecting the dots on fibroblast growth factor 23 and left ventricular hypertrophy
OM Gutiérrez |
Nephrology Dialysis Transplantation | 2016 |
Arrhythmia and Sudden Death in Hemodialysis Patients: Protocol and Baseline Characteristics of the Monitoring in Dialysis Study
DM Charytan, R Foley, PA McCullough, JD Rogers, P Zimetbaum, CA Herzog, JA Tumlin |
Clinical journal of the American Society of Nephrology : CJASN | 2016 |
Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy
B Dogan, IH Arikan, D Guler, N Keles, B Isbilen, F Isman, A Oguz |
International Urology and Nephrology | 2016 |
Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study
R Mehta, X Cai, J Lee, JJ Scialla, N Bansal, JH Sondheimer, J Chen, LL Hamm, AC Ricardo, SD Navaneethan, R Deo, M Rahman, HI Feldman, AS Go, T Isakova, M Wolf |
JAMA Cardiology | 2016 |
Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages
S Tanaka, S Fujita, S Kizawa, H Morita, N Ishizaka, T Shimosawa |
PloS one | 2016 |
Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia
PP Kalra, S Bhandari |
International journal of nephrology and renovascular disease | 2016 |
Bone and Mineral Metabolism: Where Are We, Where Are We Going, and How Will We Get There?
HM Kronenberg |
The Journal of clinical endocrinology and metabolism | 2016 |
Central blood pressure and chronic kidney disease
Y Ohno |
World Journal of Nephrology | 2016 |
Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors
WE Moody, CJ Ferro, NC Edwards, CD Chue, EL Lin, RJ Taylor, P Cockwell, RP Steeds, JN Townend |
Hypertension | 2016 |
Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT)
AY Adema, MA de Jong, MH de Borst, PM Wee, MG Vervloet |
Nephron. Clinical practice | 2016 |
FGF-23 and cardiovascular disease: review of literature
J Batra, RS Buttar, P Kaur, J Kreimerman, ML Melamed |
Current opinion in endocrinology, diabetes, and obesity | 2016 |
Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort
RF Dubin, R Deo, N Bansal, AH Anderson, P Yang, AS Go, M Keane, R Townsend, A Porter, M Budoff, S Malik, J He, M Rahman, J Wright, T Cappola, R Kallem, J Roy, D Sha, MG Shlipak |
Clinical journal of the American Society of Nephrology : CJASN | 2016 |
The role of phosphate in kidney disease
MG Vervloet, S Sezer, ZA Massy, L Johansson, M Cozzolino, D Fouque |
Nature Reviews Nephrology | 2016 |
Longitudinal assessment of cardiac morphology and function following kidney transplantation
C Kensinger, A Hernandez, A Bian, M Fairchild, G Chen, L Lipworth, TA Ikizler, KA Birdwell |
Clinical Transplantation | 2016 |
Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy:
JK Humalda, S Seiler-Muler, AJ Kwakernaak, MG Vervloet, G Navis, D Fliser, GH Heine, MH de Borst |
Medicine | 2016 |
Association of serum intact fibroblast growth factor 23 with left ventricular mass and different echocardiographic findings in patients on hemodialysis
AA Nassiri, MS Hakemi, R Safar-Pour, A Ahmadi, M Tohidi, BS Kashani, F Esfehani, S Alatab |
Journal of Translational Internal Medicine | 2016 |
Carboxy-terminal fragment of fibroblast growth factor 23 induces heart hypertrophy in sickle cell disease
M Courbebaisse, H Mehel, C Petit-Hoang, JA Ribeil, L Sabbah, V Tuloup-Minguez, D Bergerat, JB Arlet, A Stanislas, JC Souberbielle, HL Clésiau, R Fischmeister, G Friedlander, D Prié |
Haematologica | 2016 |
Fibroblast growth factor 23 dysregulates late sodium current and calcium homeostasis with enhanced arrhythmogenesis in pulmonary vein cardiomyocytes
SY Huang, YC Chen, YH Kao, MH Hsieh, YK Lin, CC Chung, TI Lee, WC Tsai, SA Chen, YJ Chen |
Oncotarget | 2016 |
FGF23 promotes myocardial fibrosis in mice through activation of β-catenin
H Hao, X Li, Q Li, H Lin, Z Chen, J Xie, W Xuan, W Liao, J Bin, X Huang, M Kitakaze, Y Liao |
Oncotarget | 2016 |